CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2017 ESGO Congress
Oncology Conference Multimedia
View more videos >>
Dr. Sessa Discusses ATR Inhibitors in BRCA-Mutated Tumors
Dr. Bosch on the HPV Vaccination in the Prevention of Cervical Cancer
Dr. Ledermann on the Results of the ARIEL3 Trial in Ovarian Cancer
Oncology Conference Articles
Cisplatin Chemoradiation Proves Benefit in Stage IIIB Cervical Cancer
Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.
Final Results Confirm OS Benefit Associated with Olaparib in Relapsed Platinum-Sensitive Serous Ovarian Cancer
Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.
Expert Discusses Rucaparib Maintenance in Ovarian Cancer
Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.
Survey Shows Patients Consider Several Factors of Maintenance Therapy for Ovarian Cancer Treatment
Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.
PALB2 Mutation Implicated in Higher Risk of Breast Cancer, Not Ovarian
Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.
Maintenance Rucaparib Extended PFS in Women with Platinum-Sensitive Recurrent Ovarian Cancer
Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.
Secondary Cytoreductive Surgery Shows Promise in Ovarian Cancer
Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.
Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer
A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.
No Overall Survival Advantage in Frontline Nintedanib With Chemotherapy in Advanced Ovarian Cancer
The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.
Salvage Surgery Improved PFS in Platinum-Sensitive Recurrent Ovarian Cancer
Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.
Immunotherapy in NSCLC: Audience Q&A
FDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer
Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial
Specialization Trend Is Changing the Oncology Landscape
FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.